GEN Exclusives

More »

GEN News Highlights

More »
May 21, 2008

Prana Obtains $6.74M Placement to Fund CNS Disease Drug Development

  • Prana Biotechnology raised over A$7 million, or approximately $6.74 million, through a private placement. The transaction included existing investors and represents a price of about $0.38 a share.

    Proceeds will advance development of the company's treatments for Alzheimer's and other neurodegenerative diseases such as Parkinson's and Huntington's diseases.

    “We are particularly gratified by the increased confidence shown by these investors who previously invested approximately six months ago at a value almost 50 percent below today's level,” states Geoffrey Kempler, chairman and CEO.

    “Since then we have achieved key milestones including a successful Phase IIa clinical trial of PBT2 and commencement of commercial discussions as well as the widening of our pipeline opportunities into different indications” Kempler continues. "We are progressing discussions with potential pharmaceutical partners and are confident that PBT2, our lead drug for Alzheimer's disease, offers a very attractive opportunity.”


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »